Karch, André
,
Schindler, Daniela
Kühn-Steven, Andrea
Blaser, Rainer
Kuhn, Klaus A.
Sandmann, Lisa
Sommerer, Claudia
Guba, Markus
Heemann, Uwe
Strohäker, Jens
Glöckner, Stephan
Mikolajczyk, Rafael
Busch, Dirk H.
Schulz, Thomas F.
Funding for this research was provided by:
Bundesministerium für Forschung und Technologie (DZIF, funding number TTU 07.701)
Projekt DEAL
Article History
Received: 15 October 2020
Accepted: 19 December 2020
First Online: 25 January 2021
Compliance with ethical standards
:
: Jörg Janne Vehreschild has received personal fees from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/Congress and Communication, Academy for Infectious Medicine, University of Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), and grants from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), (PJ-T: DLR), University of Bristol, Rigshospitalet Copenhagen. Christian Morath is the Chief Scientific Officer of TelerogenixX GmbH, and holds patents and licenses for immune cell therapy for the prevention of transplant rejection. Karl Heinz Weiss has received personal fees from Curest and Novartis for consultancies in advisory boards.
: Ethics approval was granted by the Ethics Committees of the participating centres (Hannover Medical School Nr 6534, Medical Faculty of the University of Heidelberg Nr S-585/2013, Medical Faculty of the TU Munich Nr 5926/13, LMU Munich Nr 380-15, University Hospital Tübingen Nr 327/2014BO1).
: All participants (or their legal guardians) provided written informed consent.